Skip to main content
Erschienen in: Annals of Surgical Oncology 6/2018

10.04.2018 | Gynecologic Oncology

Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE

verfasst von: Frédéric Mercier, MD, MSc, Naoual Bakrin, MD, PhD, David L. Bartlett, MD, Diane Goere, MD, François Quenet, MD, Frédéric Dumont, MD, Bruno Heyd, MD, PhD, Karine Abboud, MD, Christelle Marolho, MSc, Laurent Villeneuve, PhD, Olivier Glehen, MD, PhD, the PSOGI Working Group, the BIG-RENAPE Working Group

Erschienen in: Annals of Surgical Oncology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Ovarian cancer is the most common deadly cancer of gynecologic origin. Patients often are diagnosed at advanced stage with peritoneal metastasis. There are many rare histologies of ovarian cancer; some have outcomes worse than serous ovarian cancer. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be considered for patients with recurrence. This study was designed to assess the impact of CRS and HIPEC on survival of patient with peritoneal metastasis from rare ovarian malignancy.

Methods

A prospective, multicentric, international database was retrospectively searched to identify all patients with rare ovarian tumor (mucinous, clear cells, endometrioid, small cell hypercalcemic, and other) and peritoneal metastasis who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI) and BIG-RENAPE working group. The postoperative complications, long-term results, and principal prognostic factors were analyzed.

Results

The analysis included 210 patients with a median follow-up of 43.5 months. Median overall survival (OS) was 69.3 months, and the 5-year OS was 57.7%. For mucinous tumors, median OS and DFS were not reached at 5 years. For granulosa tumors, median overall survival was not reached at 5 years, and median DFS was 34.6 months. Teratoma or germinal tumor showed median overall survival and DFS that were not reached at 5 years. Differences in OS were not statistically significant between histologies (p = 0.383), whereas differences in DFS were (p < 0.001).

Conclusions

CRS and HIPEC may increases long-term survival in selected patients with peritoneal metastasis from rare ovarian tumors especially in mucinous, granulosa, or teratoma histological subtypes.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Bhatt A, Glehen O. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer: a review. Indian J Surg Oncol. 2016;7(2):188–97.CrossRefPubMedPubMedCentral Bhatt A, Glehen O. The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer: a review. Indian J Surg Oncol. 2016;7(2):188–97.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C,Werner L, Gülten O. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99(7):424–7.CrossRefPubMed Sehouli J, Senyuva F, Fotopoulou C, Neumann U, Denkert C,Werner L, Gülten O. Intra-abdominal tumor dissemination pattern and surgical outcome in 214 patients with primary ovarian cancer. J Surg Oncol. 2009;99(7):424–7.CrossRefPubMed
4.
Zurück zum Zitat Bamias A, Psaltopoulou T, Sotiropoulou M et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116:1462–8.CrossRefPubMed Bamias A, Psaltopoulou T, Sotiropoulou M et al. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010;116:1462–8.CrossRefPubMed
5.
6.
Zurück zum Zitat Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–7.CrossRefPubMed Winter WE III, Maxwell GL, Tian C, et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol. 2007;25:3621–7.CrossRefPubMed
7.
Zurück zum Zitat Efstathoiou E, Dimopoulos MA, Bozas G, et al. Advanced epithelial ovarian cancer in the elderly. Anticancer Res. 2007;27:611–7. Efstathoiou E, Dimopoulos MA, Bozas G, et al. Advanced epithelial ovarian cancer in the elderly. Anticancer Res. 2007;27:611–7.
8.
Zurück zum Zitat Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006;102:285–91.CrossRefPubMed Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience. Gynecol Oncol. 2006;102:285–91.CrossRefPubMed
9.
Zurück zum Zitat Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99:653–8.CrossRefPubMed Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008;99:653–8.CrossRefPubMed
10.
Zurück zum Zitat Witkowski L, Goudie C, Foulkes WD and McCluggage GW. Small-cell carcinoma of the ovary of hypercalcemic type (malignant rhabdoid tumor of the ovary) a review with recent developments on pathogenesis. Surg Pathol. 2016;9:215–26.CrossRef Witkowski L, Goudie C, Foulkes WD and McCluggage GW. Small-cell carcinoma of the ovary of hypercalcemic type (malignant rhabdoid tumor of the ovary) a review with recent developments on pathogenesis. Surg Pathol. 2016;9:215–26.CrossRef
11.
Zurück zum Zitat Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578–89.CrossRefPubMed Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: a systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578–89.CrossRefPubMed
12.
Zurück zum Zitat Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58. Jacquet P, Sugarbaker PH. Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res. 1996;15:49–58.
13.
Zurück zum Zitat Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefPubMed Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefPubMed
14.
Zurück zum Zitat Glehen O, Mohammed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5(4):219–28.CrossRefPubMed Glehen O, Mohammed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5(4):219–28.CrossRefPubMed
16.
Zurück zum Zitat Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRefPubMed Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRefPubMed
17.
Zurück zum Zitat Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med. 2004;351:2544–6.CrossRefPubMed Thigpen T. The if and when of surgical debulking for ovarian carcinoma. N Engl J Med. 2004;351:2544–6.CrossRefPubMed
18.
Zurück zum Zitat Amate P, Huchon C, Dessapt AL, et al. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer. 2013;23(9):1590–6.CrossRefPubMed Amate P, Huchon C, Dessapt AL, et al. Ovarian cancer: sites of recurrence. Int J Gynecol Cancer. 2013;23(9):1590–6.CrossRefPubMed
19.
Zurück zum Zitat Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.CrossRefPubMed Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;13(12):1702–10.CrossRefPubMed
20.
Zurück zum Zitat Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103(3):1070–6.CrossRefPubMed Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006;103(3):1070–6.CrossRefPubMed
21.
Zurück zum Zitat Prat J. Staging classification for the cancer of the ovary, fallopian tube and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.CrossRefPubMed Prat J. Staging classification for the cancer of the ovary, fallopian tube and peritoneum. Int J Gynaecol Obstet. 2014;124:1–5.CrossRefPubMed
22.
Zurück zum Zitat Harter P, Sehouli J, Lorusso D, et al. LION: lymphadenectomy in ovarian neoplasms-A prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol. 2017;35:5500. Harter P, Sehouli J, Lorusso D, et al. LION: lymphadenectomy in ovarian neoplasms-A prospective randomized AGO study group led gynecologic cancer intergroup trial. J Clin Oncol. 2017;35:5500.
23.
Zurück zum Zitat Baumgartner JM, Tobin L, Heavey SF, et al. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(5):1716–21.CrossRefPubMed Baumgartner JM, Tobin L, Heavey SF, et al. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2015;22(5):1716–21.CrossRefPubMed
24.
Zurück zum Zitat El Halabi H, Gushchin V, Francis J, et al. The role of cytoredcutive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19(1):110–4.CrossRefPubMed El Halabi H, Gushchin V, Francis J, et al. The role of cytoredcutive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) in patients with high-grade appendiceal carcinoma and extensive peritoneal carcinomatosis. Ann Surg Oncol. 2012;19(1):110–4.CrossRefPubMed
25.
Zurück zum Zitat Miner TJ, Shia J, Jacques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–8.CrossRefPubMedPubMedCentral Miner TJ, Shia J, Jacques DP, et al. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. 2005;241:300–8.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Bakrin N, Bereder JM, Decullier E, Classe JM, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–43.CrossRefPubMed Bakrin N, Bereder JM, Decullier E, Classe JM, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435–43.CrossRefPubMed
27.
Zurück zum Zitat Lee YY, et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol. 2011;122(3):541–7.CrossRefPubMed Lee YY, et al. Prognosis of ovarian clear cell carcinoma compared to other histological subtypes: a meta-analysis. Gynecol Oncol. 2011;122(3):541–7.CrossRefPubMed
28.
Zurück zum Zitat Davis M, Rauh-Hain JA, Andrade C, et al. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014;132:760–6.CrossRefPubMed Davis M, Rauh-Hain JA, Andrade C, et al. Comparison of clinical outcomes of patients with clear cell and endometrioid ovarian cancer associated with endometriosis to papillary serous carcinoma of the ovary. Gynecol Oncol. 2014;132:760–6.CrossRefPubMed
29.
Zurück zum Zitat Hayes-Jordan A, Lopez C, Green HL et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach. Pediatr Surg Int. 2016;32(1):71–3.CrossRefPubMedPubMedCentral Hayes-Jordan A, Lopez C, Green HL et al. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric ovarian tumors: a novel treatment approach. Pediatr Surg Int. 2016;32(1):71–3.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic cooperative oncology group experience. Gynecol Oncol. 2005;97:436–41.CrossRefPubMed Pectasides D, Fountzilas G, Aravantinos G, et al. Advanced stage mucinous epithelial ovarian cancer: the Hellenic cooperative oncology group experience. Gynecol Oncol. 2005;97:436–41.CrossRefPubMed
31.
Zurück zum Zitat Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480.e1–8. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480.e1–8.
32.
Zurück zum Zitat Chan JK, Zhang M, Kaleb V, et al. Prognostic factors responsible for survival in sex cord stromal tumor of the ovary: a multivariate analysis. Gynecol Oncol. 2005;96:204–9.CrossRefPubMed Chan JK, Zhang M, Kaleb V, et al. Prognostic factors responsible for survival in sex cord stromal tumor of the ovary: a multivariate analysis. Gynecol Oncol. 2005;96:204–9.CrossRefPubMed
33.
Zurück zum Zitat Seagle BL, Ann P, Butler S, Shahabi S. Ovarian granulosa cell tumor: a National Cancer Database study. Gynecol Oncol. 2017;146(2):285–91.CrossRefPubMed Seagle BL, Ann P, Butler S, Shahabi S. Ovarian granulosa cell tumor: a National Cancer Database study. Gynecol Oncol. 2017;146(2):285–91.CrossRefPubMed
34.
Zurück zum Zitat Gouy S, Uzan C, Pautier P et al. Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):464–7.CrossRefPubMed Gouy S, Uzan C, Pautier P et al. Results of oxaliplatin-based hyperthermic intraperitoneal chemotherapy in recurrent ovarian granulosa cell tumors. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):464–7.CrossRefPubMed
35.
Zurück zum Zitat Al-Badawi IA, Abu-Zaid A, Azzam A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management for recurrent/relapsed ovarian granulosa cell tumor: a single center experience. J Obstet Gynaecol Res. 2014;40(9):2066–75.CrossRefPubMed Al-Badawi IA, Abu-Zaid A, Azzam A, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for management for recurrent/relapsed ovarian granulosa cell tumor: a single center experience. J Obstet Gynaecol Res. 2014;40(9):2066–75.CrossRefPubMed
36.
Zurück zum Zitat Pashankar F, Hale JP, Dang H, et al. Is adjuvant chemotherapy indicated in ovarian immature teratoma? A combined data analysis from the malignant germ cell tumor international collaborative. Cancer. 2016;122(2):230–7.CrossRefPubMed Pashankar F, Hale JP, Dang H, et al. Is adjuvant chemotherapy indicated in ovarian immature teratoma? A combined data analysis from the malignant germ cell tumor international collaborative. Cancer. 2016;122(2):230–7.CrossRefPubMed
37.
Zurück zum Zitat Poujade O, Uzan C, Gouy S, et al. Primary psammocarcinoma of the ovary or peritoneum. Int J Gynecol Cancer. 2009;19(5):844–6.CrossRefPubMed Poujade O, Uzan C, Gouy S, et al. Primary psammocarcinoma of the ovary or peritoneum. Int J Gynecol Cancer. 2009;19(5):844–6.CrossRefPubMed
38.
Zurück zum Zitat WItkowski L, Goudie C, Foulkes WD, McCluggage WG. Small-cell carcinoma of the ovary of hypercalcemic type (malignant rhabdoid tumor of the ovary): a review with recent development on pathogenesis. Surg Pathol Clin. 2016;9:215–26. WItkowski L, Goudie C, Foulkes WD, McCluggage WG. Small-cell carcinoma of the ovary of hypercalcemic type (malignant rhabdoid tumor of the ovary): a review with recent development on pathogenesis. Surg Pathol Clin. 2016;9:215–26.
39.
Zurück zum Zitat Chua TC, Moran BJ, Sugarbaker PH, et al. Early and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.CrossRefPubMed Chua TC, Moran BJ, Sugarbaker PH, et al. Early and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.CrossRefPubMed
40.
Zurück zum Zitat Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.CrossRefPubMed Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34–43.CrossRefPubMed
41.
Zurück zum Zitat Walker JL, Brady MF, DiSilvestro PA, et al. A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): A GOG/NRG trial (GOG 252). 2016 Society of Gynecologic Oncology Annual Meeting. Late-breaking abstract 6. Presented March 21, 2016. Walker JL, Brady MF, DiSilvestro PA, et al. A phase III trial of bevacizumab with IV versus IP chemotherapy in ovarian, fallopian tube, and peritoneal carcinoma NCI-supplied agent(s): A GOG/NRG trial (GOG 252). 2016 Society of Gynecologic Oncology Annual Meeting. Late-breaking abstract 6. Presented March 21, 2016.
42.
Zurück zum Zitat Van Driel, WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Eng J Med. 2018;378:230–40.CrossRef Van Driel, WJ, Koole SN, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Eng J Med. 2018;378:230–40.CrossRef
43.
Zurück zum Zitat Passot G, Vaudoyer D, Villeneuve L, et al. What made hyperthermic intraperitnoeal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1125 procedures. J Surg Oncol. 2016;113:796–803.CrossRefPubMed Passot G, Vaudoyer D, Villeneuve L, et al. What made hyperthermic intraperitnoeal chemotherapy an effective curative treatment for peritoneal surface malignancy: a 25-year experience with 1125 procedures. J Surg Oncol. 2016;113:796–803.CrossRefPubMed
Metadaten
Titel
Peritoneal Carcinomatosis of Rare Ovarian Origin Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Multi-Institutional Cohort from PSOGI and BIG-RENAPE
verfasst von
Frédéric Mercier, MD, MSc
Naoual Bakrin, MD, PhD
David L. Bartlett, MD
Diane Goere, MD
François Quenet, MD
Frédéric Dumont, MD
Bruno Heyd, MD, PhD
Karine Abboud, MD
Christelle Marolho, MSc
Laurent Villeneuve, PhD
Olivier Glehen, MD, PhD
the PSOGI Working Group
the BIG-RENAPE Working Group
Publikationsdatum
10.04.2018
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 6/2018
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6464-z

Weitere Artikel der Ausgabe 6/2018

Annals of Surgical Oncology 6/2018 Zur Ausgabe

Häusliche Gewalt in der orthopädischen Notaufnahme oft nicht erkannt

28.05.2024 Häusliche Gewalt Nachrichten

In der Notaufnahme wird die Chance, Opfer von häuslicher Gewalt zu identifizieren, von Orthopäden und Orthopädinnen offenbar zu wenig genutzt. Darauf deuten die Ergebnisse einer Fragebogenstudie an der Sahlgrenska-Universität in Schweden hin.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mehr Frauen im OP – weniger postoperative Komplikationen

21.05.2024 Allgemeine Chirurgie Nachrichten

Ein Frauenanteil von mindestens einem Drittel im ärztlichen Op.-Team war in einer großen retrospektiven Studie aus Kanada mit einer signifikanten Reduktion der postoperativen Morbidität assoziiert.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.